Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. is dated July 15, 2015, covering the month of July 2015. The document serves as an issuer free writing prospectus pursuant to Rule 433 of the Securities Act of 1933. It incorporates by reference a press release announcing the size of a proposed public offering of the company's American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing related to a securities offering and does not contain a financial statement or operational data summary.
Material Changes
No material changes to financial performance or operations are reported in this specific filing. The primary event disclosed is the announcement regarding the size of a proposed public offering of ADSs.
Guidance, Outlook, and Risks
The filing references a shelf registration statement and a preliminary prospectus supplement filed with the SEC. It explicitly states that this Form 6-K does not constitute an offer to sell or a solicitation of an offer to buy ADSs in jurisdictions where such actions would be unlawful prior to registration. Investors are directed to read the full prospectus and other SEC filings for complete information regarding risks and contingencies.
Investor Verification Checklist
- Verify the final size and terms of the proposed public offering of ADSs in the full prospectus.
- Review the preliminary prospectus supplement filed on July 14, 2014, and the effective shelf registration statement (Registration No. 333-193503).
- Confirm the underwriters involved: Nomura Securities International, Inc. and Roth Capital Partners.
- Check the SEC EDGAR database for the complete Registration Statement on Form F-3 and Form S-8 for detailed risk factors.